On Oct. 6, 2020, Oragenics announced receipt of feedback to its Type B Pre-IND Meeting Request from the FDA that it was in broad agreement with the Companyﾒs planned approach to clinical development of its SARS-CoV-2 vaccine, Terra CoV-2. Oragenics expects to file the IND by the end of the first quarter of 2021 and commence patient enrollment in the Phase 1 clinical study early in the second quarter of 2021.